Burixafor (TG-0054) vs Motixafortide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CXCR4 · full Multiple Myeloma pipeline
Burixafor (TG-0054)
Developed by GPCR Therapeutics, Inc. and partners
NCT01018979 · Phase 2 · completed
Although this study assigned patients to two dose levels, it had no placebo or active-comparator arm and was fully open-label (no masking), so there was no control against which to judge the drug's effect. Only 19 patients were treated, and most (13 of 19) dropped out before completing collection because their stem cell counts never rose high enough, leaving just 4 and 3 patients per dose group who even underwent apheresis for the primary mobilization-success endpoint. With no control arm and such a small, high-dropout sample, this is uncontrolled, exploratory evidence rather than a definitive efficacy trial.
Reported efficacy
Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5 (not_applicable)
Result source: NCT01458288
Motixafortide
Marketed by Ayrmid Ltd. and partners
NCT03246529 · Phase 3 · active, not recruiting
GENESIS was a randomized, double-blind, placebo-controlled Phase 3 trial in patients with multiple myeloma. In Part 2, 122 patients were randomized 2:1 to motixafortide (n=80) or placebo (n=42), each given with filgrastim. The single primary endpoint was the proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses, read by the central laboratory. The FDA label reports 67.5% with motixafortide and 9.5% with placebo (p < 0.0001), so the primary endpoint was met. The endpoint is a stem-cell collection count, which is a surrogate for transplant outcomes. Source: the APHEXDA US label, section 14, and the ClinicalTrials.gov posted results.
Next expected readout: December 2026 · NCT07101445 (registry estimate)
Reported efficacy
Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions (From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6): Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel). (met)
Result source: NCT03246529
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Burixafor (TG-0054) | Motixafortide |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT03246529 |
| OS, median | —Not reported | —Trial running · NCT03246529 |
| ORR | —Not reported | —Trial running · NCT03246529 |
| VGPR or better | —Not reported | —Trial running · NCT03246529 |
| MRD negativity | —Not reported | —Trial running · NCT03246529 |
PFS, median
- Burixafor (TG-0054)
- —Not reported
- Motixafortide
- —Trial running · NCT03246529
OS, median
- Burixafor (TG-0054)
- —Not reported
- Motixafortide
- —Trial running · NCT03246529
ORR
- Burixafor (TG-0054)
- —Not reported
- Motixafortide
- —Trial running · NCT03246529
VGPR or better
- Burixafor (TG-0054)
- —Not reported
- Motixafortide
- —Trial running · NCT03246529
MRD negativity
- Burixafor (TG-0054)
- —Not reported
- Motixafortide
- —Trial running · NCT03246529
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Burixafor (TG-0054): 4 of 5 rows · Motixafortide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Burixafor (TG-0054) | Motixafortide |
|---|---|---|
| CD34 Target Achievement event count · % of participants No placebo or comparator arm | 100% (n=7) @ 1wk*3.14 mg/kga,b,c,d NCT01458288 · Phase 2 · monotherapy · converted to % from 7 participants as posted show 1 more dose100% (n=5) @ 1wk*3.14 mg/kg + G-CSF NCT01458288 · Phase 2 · combination · converted to % from 5 participants as posted | 91.7% (n=24) @ 0.29wk*a,b,c,d NCT02639559 · Phase 2 · converted to % from 22 Participants as posted show 1 more dose100% (n=9) @ 0.29wk* NCT02639559 · Phase 2 · converted to % from 9 Participants as posted |
| Dropout rate | 76.9%3.14 mg/kge NCT01018979 · Phase 2 · monotherapy show 3 more results42.9%2.24 mg/kg NCT01018979 · Phase 2 · monotherapy —3.14 mg/kg IV NCT01458288 · Phase 2 · monotherapy —3.14 mg/kg NCT02104427 · Phase 2 · registry result, not featured evidence · combination | —BL-8040 + G-CSF (Part 2)f NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results0%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 7.5%BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 4% NCT02639559 · Phase 2 |
| Discontinued due to AEs | —3.14 mg/kge NCT01018979 · Phase 2 · monotherapy show 3 more results—2.24 mg/kg NCT01018979 · Phase 2 · monotherapy —3.14 mg/kg IV NCT01458288 · Phase 2 · monotherapy —3.14 mg/kg NCT02104427 · Phase 2 · registry result, not featured evidence · combination | —BL-8040 + G-CSF (Part 2)f NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results0%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 2.5%BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 — NCT02639559 · Phase 2 |
| Serious AEs | 50%3.14 mg/kge NCT01018979 · Phase 2 · monotherapy show 3 more results28.6%2.24 mg/kg NCT01018979 · Phase 2 · monotherapy 0%3.14 mg/kg IV NCT01458288 · Phase 2 · monotherapy 0%3.14 mg/kg NCT02104427 · Phase 2 · registry result, not featured evidence · combination | 8.8%BL-8040 + G-CSF (Part 2)f NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 3 more results8.3%BL-8040 + G-CSF Part 1 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 —BL-8040 + G-CSF Part 2 NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 0% NCT02639559 · Phase 2 |
| Most frequent reported AEs | 3.14 mg/kge leukocytosis 16.7% cardiac disorders-other:qt prolong at 24hr-36hr after infusion 8.3% diarrhea 8.3% NCT01018979 · Phase 2 · monotherapy show 3 more results3.14 mg/kg IV diarrhoea 33.3% neuropathy peripheral 33.3% abdominal pain 16.7% NCT01458288 · Phase 2 · monotherapy 3.14 mg/kg diarrhoea 8.3% dry mouth 8.3% hypokalaemia 8.3% NCT02104427 · Phase 2 · registry result, not featured evidence · combination | f injection site pain 50% (placebo 4.8%) pruritus 32.5% (placebo 0%) injection site erythema 27.5% (placebo 0%) NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 show 2 more resultsinjection site pain 75% (placebo 4.8%) pruritus 66.7% (placebo 0%) injection site pruritus 41.7% (placebo 0%) NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 lymphocyte count increased 88% platelet count decreased 88% allergic reaction 80% NCT02639559 · Phase 2 |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bOne study enrolled healthy volunteers and the other enrolled patients.
- cPopulation context differs: registered conditions differ.
- dAssessment timepoints differ: 0.29 weeks versus 1 weeks.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Burixafor (TG-0054)
show 1 more result
Motixafortide
show 1 more result
show 1 more result
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Burixafor (TG-0054)'s landscape · Motixafortide's landscape